(43 mg, 0.031 mmol, 5%). White colour powder of 7. Yield:
92 mg (51%) H NMR (400 MHz, CDCl3-d1, δppm): 10.13 (s,
(63%).1H-NMR (400 MHz, CDCl3-d1, δppm): 8.62 (s, 2H), 8.14
(s, 1H), 8.01 (s, 1H), 7.79–7.72 (m, 6H), 6.55 (s, 2H), 5.30 (s,
1H, N−CH−N), 4.30–4.12 (m, 2H), 1.33–1.13 (m, 12H).
13C-NMR (100 MHz, CDCl3-d1, δppm) δ: 154.4, 150.6, 142.3,
137.5, 129.2, 127.6, 127.2, 126.5, 125.5, 107.9, 107.4, 62.1,
31.9, 31.4, 31.0, 29.7, 29.4, 25.3, 23.6, 23.0, 22.7, 14.1. LCMS
analysis (m/z) found 472.00; calcd 471.56. FT-IR (KBr): 3435.5,
3288.9, 3165.5, 2999.6, 1701.4, 1641.6, 1566.3, 1413.9, 1049.4,
1012.7, 923.99, 810.2, 650.1, 623.1, 522.8, 464.9 cm−1. Anal.
calcd for C25H29N5O (471.25): found C, 63.58; N, 26.45; H,
6.25; requires, 63.68; H, 6.20; N, 26.73%.
1
1H, –CHO), 8.62–8.61 (d, 2H), 8.32 (t, 1H), 8.15 (s, 2H),
8.10–8.08 (m, 1H), 8.01 (m, 1H), 7.8 (d, 2H), 7.71–7.67 (t, 1H),
6.54–6.53 (q, 2H). 13CNMR (100 MHz, CDCl3-d1, δppm): 191.7,
152.7, 150.8, 142.6, 138.5, 137.2, 133.0, 130.5, 129.9, 128.6,
127.3, 108.2, 107.3. LCMS analysis (m/z): found 316.10; calcd
315.11. FT-IR (KBr): 3432, 2963, 1699 (–CHO), 1618, 1562,
1522, 1470, 1399, 1262, 1036, 949, 862, 799, 540 cm−1. Anal.
calcd for C18H13N5O (315.11): found C 68.65, N 22.45, H
4.09%; requires C 68.56, N 22.21, H 4.16%.
5-(2,6-Di(pyrazol-1-yl)pyridin-4-yl)isophthalaldehyde (9).
Similar procedure for the synthesis of 8 was applied. 4′-Iodo-
2′,6′-dipyrazolyl-pyridine (200 mg, 0.59 mmol), 3,5-diformyl-
phenylboronic acid (126 mg, 0.712 mmol) and Pd(PPh3)4
(80 mg, 0.031 mmol, 5%). White colour powder of 9. Yield:
6,6′-(5-(2,6-Di(pyrazol-1-yl)pyridin-4-yl)-1,3-phenylene)bis
(2,4-diisopropyl-1,2,4,5-tetrazinan-3 one) (15). Compound 15
also synthesized by same procedure. 2,4-Diisopropylcarbono-
hydrazide bishydrochloride (152 mg, 0.87 mmol), 5-(2,6-di
(pyrazol-1-yl)pyridin-4-yl)isophthalaldehyde (9) (100 mg,
0.343 mmol), and sodium acetate (72 mg, 0.87 mmol). Yield:
1
125 mg (58%). H-NMR (400 MHz, CDCl3-d1, δppm): 10.21 (s,
1
2H, –CHO), 8.62–8.56 (d, 4H), 8.48 (s, 1H), 8.18 (s, 2H), 7.81
(s, 2H), 6.55 (m, 2H). 13C-NMR (100 MHz, CDCl3-d1, δppm) δ:
190.4, 151.3, 151.0, 142.8, 139.8, 137.9, 133.1, 131.2, 127.3,
108.4, 107.2. LCMS analysis (m/z): found 344.0; calcd 343.11.
FT-IR (KBr): 3403, 2919, 1698(–CHO), 1616, 1464, 1397,
1262, 1020, 801 cm−1. Anal. calcd for C18H13N5O (541.82):
found C, 66.32; N 20.54, H 3.88%; requires C 68.47, N 20.40,
H 3.82%.
111 mg (59%). H-NMR (400 MHz, CDCl3-d1, δppm): 8.58 (s,
2H), 8.11 (s, 2H), 7.86 (s, 1H), 7.75 (m, 4H), 6.48 (s, 2H), 5.24
(s, 2H, N−CH−N), 4.88–4.13 (m, 4H), 1.23–1.05 (m, 24H).
13C-NMR (100 MHz, CDCl3-d1, δppm) δ: 154.0, 150.6, 149.9,
147.1, 145.8, 142.7, 136.5, 127.2, 107.9, 107.4, 63.6, 31.9,
31.4, 31.0, 29.7, 29.4, 25.3, 23.6, 23.0, 22.7, 14.2. LCMS analy-
sis (m/z): found 655.60; calcd 655.80. Anal. calcd for
C33H45N13O2 (655.80): found C, 60.58; N, 27.45; H, 6.85%;
requires, C, 60.44; H, 6.92; N, 27.77%; FT-IR (KBr): 3435.5,
3288.9, 2980.3, 2935.9, 2878.1, 1738.0, 1707.2, 1641.6, 1564.4,
1412.0, 1250, 1155.5, 1045.5, 1012.7, 920.1, 852.6, 788.9,
General procedure for tetrazanes
646.2, 530.5 cm−1
.
6-(3-(2,6-Di(pyrazol-1-yl)pyridin-4-yl)phenyl)-2,4-diisopro-
pyl-1,2,4,5-tetrazinan-3-one (13). In a typical procedure, 2,4-di-
isopropylcarbonohydrazide
bishydrochloride
(81
mg,
General procedure for 4,4,5,5-tetramethylimidazolidines
0.468 mmol) and 3-(2,6-di(pyrazol-1-yl)pyridin-4-yl)benz-
aldehyde (7) (100 mg, 0.312 mmol) were dissolved completely
in a minimum amount of ethanol (10 mL). To this clear solution
was added sodium acetate (51 mg, 0.624 mmol) and the solution
was allowed to stir at room temperature for 15 h (no noticeable
colour change was found). The turbid solution was filtered to
remove the sodium acetate and the filtrate was evaporated
in vacuo to get a yellowish-white residue. The residue was
recrystallized from heptane to get white colour tetrazane com-
2,6-Di(pyrazol-1-yl)-4-(4-(4,4,5,5-tetramethylimidazolidin-2-
yl)phenyl)pyridine (11). In a typical procedure, a solution of
4–2,6-di(pyrazol-1-yl)pyridin-4-yl-benzaldehyde (8) (200 mg,
0.634 mmol) in chloroform (10 mL) was added drop-wise
to a solution of 2,3-diamino-2,3-dimethylbutane (110 mg,
0.952 mmol) in chloroform (20 mL) in a round bottom flask.
The reaction mixture was heated at 60 °C for 2 d under argon to
get a light turbid solution. The TLC confirmed the complete con-
sumption of 8 (Rf = 0.55; 3 : 2 DCM–hexane). The solution was
directly dried with Na2SO4 and evaporated in vacuo to get com-
1
pound 13. Yield: 87 mg (60%). H-NMR (400 MHz, CDCl3-d1,
δppm): 8.62–8.61 (d, 2H), 8.14 (s, 2H), 8.01 (s, 1H), 7.79–7.72
(m, 4H), 7.51–7.49 (m, 1H), 6.52 (d, 2H), 5.29 (s, 1H, N−CH
−N), 4.88–4.16 (m, 2H), 1.33–1.13 (m, 12H). 13C-NMR
(100 MHz, CDCl3-d1, δppm) δ: 154.4, 150.9, 149.1, 146.5,
142.6, 132.3, 132.2, 131.5, 128.6, 128.5, 127.1, 108.1, 107.8,
63.0, 31.9, 31.4, 31.0, 29.7, 29.4, 25.3, 23.6, 23.0, 22.7, 14.1.
LCMS analysis (m/z): found 471.30; calcd 471.56. FT-IR (KBr):
2982, 1722, 1647, 1574, 1417, 1255, 1105, 1051, 771, 652, 623,
457 cm−1. Anal. calcd for C25H29N5O (471.25): found C 63.48,
N 26.59, H 6.25%; requires C, 63.68; H, 6.20; N, 26.73%.
1
pound 11 as a white powder. Yield: 172 mg (66%). H-NMR
(400 MHz, CDCl3-d1, δppm): 8.63 (s, 2H), 8.18 (s, 2H), 7.84,
7.82, 7.8, 7.73, 6.53 (s, 2H), 5.27 (s, 1H, N–CH–N), 1.25, 1.23,
1.13. 13C-NMR (100 MHz, CDCl3-d1, δppm): 153.9, 150.6,
145.8, 142.4, 136.5, 127.2, 108.0, 107.2, 73.0, 63.0, 31.0, 25.3,
23.6, 14.2. LCMS analysis (m/z): found, 414.25; calcd, 413.52.
FT-IR (KBr): 3335, 2978, 2919, 2855, 1615, 1541, 1460, 1391,
1273, 1171, 694 cm−1. Anal. Calcd for C18H13N5O (541.82):
found C 69.58, N 23.85, H 6.51. Required C, 69.71; H, 6.58; N,
23.71.
6-(4-(2,6-Di(pyrazol-1-yl)pyridin-4-yl)phenyl)-2,4-diisopro-
pyl-1,2,4,5-tetrazinan-3-one(14). Compound 14 was synthesized
by above tetrazane procedure. 2,4-Diisopropylcarbonohydrazide
bishydrochloride (81 mg, 0.468 mmol), 4-(2,6-di(pyrazol-1-yl)
pyridin-4-yl)benzaldehyde (8) (100 mg, 0.312 mmol), and
sodium acetate (51 mg, 0.624 mmol). Yield: 93 mg
2,6-Di(pyrazol-1-yl)-4-(3-(4,4,5,5-tetramethylimidazolidin-2-
yl)phenyl)pyridine(10). Compound 10 was synthesized by above
condensation procedure. 3-(2,6-Di(pyrazol-1-yl)pyridin-4-yl)
benzaldehyde (7) (200 mg, 0.634 mmol) and 2,3-diamino-2,3-
dimethylbutane (110 mg, 0.952 mmol) Yield: 163 mg (62%);
2444 | Org. Biomol. Chem., 2012, 10, 2439–2446
This journal is © The Royal Society of Chemistry 2012